医学
免疫疗法
癌症研究
肿瘤微环境
结直肠癌
血管生成
癌症
肺癌
癌症免疫疗法
血管内皮生长因子受体
肿瘤细胞
肿瘤进展
肿瘤科
子宫内膜癌
贝伐单抗
临床试验
细胞
靶向治疗
血管内皮生长因子
内科学
免疫学
肾细胞癌
索拉非尼
生物信息学
转移
肝细胞癌
作者
Magali Terme,Morgane Bourhis,Arthur Daban,Claire Gallois,Fangyi Chen,Julien Taïeb
标识
DOI:10.1158/1078-0432.ccr-25-3556
摘要
VEGF-A/VEGF-R axis is well recognized for its role in tumor angiogenesis as well as tumor-induced immunosuppressive mechanisms. Targeting this pathway can help to switch tumor microenvironment toward a more immune-permissive state. Inhibition of VEGF-A/VEGFR has emerged as a strategy to enhance the efficacy of immunotherapy in some cancers leading to the approval of anti-VEGF-A/anti-PD(L)1 combinations in advanced renal cell cancer, hepatocellular carcinoma, non-small cell lung cancer, and endometrial cancer. However, in other tumor types, and particularly in colorectal cancer or glioblastoma, results remain limited. In this review, we discuss the biological rationale underlying anti-VEGF-A/PD-(L)1 combinations, summarize the clinical evidence supporting their use across tumor types, discuss the disappointing results in colorectal cancer and glioblastoma, and highlight emerging strategies to improve their therapeutic efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI